11:30
#69 Long term results on treatment of interstitial cystitis with low dose cyclosporine A
Sairanen J. 1, Forsell T. 2, Ruutu M. 2 1. Department of Urology, Helsinki University Central Hospital, 2. Department of Urology, Helsinki University Central
11:37
#70 New use for an old drug: results of a dose titration study of intra-vesical atropine
Fader M. 1, Barton R. 1, Malone-Lee J. 1, Glickman S. 2, Gluck T. 3, Fowler C. 4, Deaney C. 5 1. University College London, 2. North West London Hospitals NHS Trust, 3. Barnet General Hospital London, 4. National Hospital for Neurology and Neurosurgery L, 5. Kings College Hospital London
11:45
#71 BETHANECHOL IN THE RESTITUTION OF THE ACONCTRACTILE DETRUSOR: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Riedl C. 1, Daha L. 2, Knoll M. 2, Pflueger H. 2 1. Hospital Baden, 2. Hospital Lainz-Vienna
11:52
#72 PERCEIVED RANDOMIZATION AFFECTS OBJECTIVE, SUBJECTIVE, AND QUALITY OF LIFE OUTCOMES IN URGE INCONTINENCE TREATMENT
DuBeau C. 1, Khullar V. 2 1. Harvard Medical School, 2. Imperial College School of Medicine
12:00
#73 Mixed Incontinence: How Should it be Treated?
Khullar V. 1, Digesu A. 1, Chaliha C. 1, Khan M. 1, Hutchins A. 1 1. Imperial College School of Medicine
12:07
#74 Transdermal oxybutynin and controlled-release oral tolterodine in patients with positive treatment effect to anticholinergic therapy for overactive bladder
Dmochowski, MD R. 1, Davila, MD W. 2, Sanders, PharmD S. 3 1. Vanderbilt University, 2. Cleveland Clinic Florida, 3. Watson Laboratories, Inc.
12:15
#75 YM905 APPEARS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH SYMPTOMATIC IDIOPATHIC DETRUSOR OVERACTIVITY IN A EUROPEAN PLACEBO- AND TOLTERODINE-CONTROLLED, PHASE-II, DOSE-FINDING STUDY
Chapple C. R. 1, Arano P. 2, Bosch J. H. R. 3, De Ridder D. 4, Kramer A. (. 5, Ridder A. M. 6 1. Royal Hallamshire Hospital, 2. Fundacion Puigvert, 3. Erasmus Medical Center, 4. University Hospitals Leuven, 5. Berufsgenossenschaftliche Unfallklinik, 6. Yamanouchi Europe B.V.
12:22
#76 Meta-analysis of placebo-controlled studies of trospium chloride 20 mg bid in patients with detrusor overactivity
Fröhlich G. 1, Bulitta M. 2 1. Medical Doctor - Urologist, 2. CRMB GmbH
12:30
#77 DULOXETINE VERSUS PLACEBO IN THE TREATMENT OF STRESS URINARY INCONTINENCE (SUI)
Zinner N. 1, Dmochowski R. 2, Miklos J. 3, Norton P. 4, Yalcin I. 5, Bump R. 5 1. Western Clinical Research, Inc., 2. Vanderbilt University, 3. Atlanta Urogynecology Associates, 4. University of Utah, 5. Eli Lilly and Company
12:37
#78 Women Take Control; Desmopressin - A Drug for Daytime Urinary Incontinence
Robinson D. 1, Cardozo L. 2, Akeson M. 3, Hvistendahl G. 4, Riis A. 5, Norgaard J. P. 5 1. Department of Urogynaecology, Kings College Hospital, 2. Kings College Hospital, 3. Boras County Hospital, Boras, Sweden, 4. Skejby Hospital, Aarhus, Denmark, 5. Ferring Pharmaceuticals, Copenhagen, Denmark
12:45
#79 Repeat detrusor injections of botulinum A toxin in patients with neurogenic lower urinary tract dysfunction do not cause increased drug tolerance.
Grosse J. 1, Kramer G. 2, Schurch B. 3, Stöhrer M. 4 1. Department of Urology, Berufsgenossenschaftliche Unfallklinik Murnau, 2. Urodynamic Unit, Berufsgenossenschaftliche Unfallk, 3. Swiss Paraplegic Centre, University Hospital Balgr, 4. Department of Urology, Berufsgenossenschaftliche U
12:52
#80 Effectiveness of periurethral botulinum toxin injection in the treatment of voiding dysfunction due to detrusor underactivity and non-relaxing urethral sphincter
Kuo H. 1 1. Buddhist Tzu Chi General Hospital